Drugs / MVA85A
MVA85A
Trials 23 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 117 trials | ||||||
| Phase 1 | NCT02532036 | Sep 2015 → Oct 2018 | tuberculosis | University of Oxford | Terminated | No outcome recorded |
| Phase 1 | NCT01954563 | Oct 2013 → Jan 2016 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT01829490 | Jul 2013 → Apr 2016 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT01683773 | Sep 2012 → Aug 2014 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT01497769 | Sep 2011 → Oct 2012 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT01194180 | May 2010 → Jan 2012 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT01181856 | Jan 2010 → Jan 2011 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT00731471 | Aug 2008 → Jan 2011 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT00548444 | Oct 2007 → Jan 2010 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT00653770 | Sep 2007 → Jan 2010 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT00460590 | Oct 2005 → Jun 2008 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT00456183 | Aug 2005 → Apr 2007 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT00427453 | Jun 2003 → Mar 2005 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT00427830 | May 2003 → Jan 2005 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT00423839 | Mar 2003 → Jul 2005 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT00046397 | Sep 2002 → Aug 2005 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00423566 | Sep 2002 → Jul 2003 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03681860 | Jul 2019 → May 2021 | — | University of Oxford | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT02178748 | Jun 2014 → Jan 2015 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT01650389 | Oct 2012 → May 2015 | HIV infectious disease, tuberculosis | Mark Hatherill | Completed | No outcome recorded |
| Phase 2 | NCT01151189 | Jul 2011 → May 2014 | HIV infectious disease, tuberculosis | Aeras | Completed | No outcome recorded |
| Phase 2 | NCT00953927 | Jul 2009 → Oct 2012 | tuberculosis | Aeras | Completed | No outcome recorded |
| Phase 2 | NCT00679159 | Feb 2008 → Dec 2009 | tuberculosis | University of Oxford | Completed | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01879163 Comparator | Jul 2013 → Dec 2014 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT00480558 Comparator | Jul 2007 → Jan 2011 | HIV infectious disease, tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT00395720 Comparator | Nov 2006 → Jul 2010 | HIV infectious disease, tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT00480454 Comparator | Oct 2006 → Dec 2009 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT00465465 Comparator | Oct 2005 → Sep 2007 | tuberculosis | University of Oxford | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 30 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA85A | “MVA85A is a modified vaccinia virus expressing antigen 85A from Mycobacterium tuberculosis which has been in clinical development since 2002 as a candidate vaccine to boost...” PMID 25466778 ↗ Dec 201429“MVA85A is a novel viral vector TB vaccine candidate designed to boost BCG-induced immunity when delivered intradermally.” PMID 23266342 ↗ Dec 2012 “Having demonstrated safety and immunogenicity of 5 x 107pfu of MVA85A, we now need to perform a dose optimization study” NCT00465465 ↗ “Biological: MVA 85A” NCT00395720 ↗ |
| Known as | AERAS-485 | “MVA85A/AERAS-485 is a recombinant modified vaccinia virus Ankara expressing the M. tuberculosis antigen, Ag85A.” NCT01151189 ↗ |
| Known as | Modified Vaccinia Virus Ankara | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00046397 ↗ |
| Known as | MVA | “experimental vaccine called Modified Vaccinia Virus Ankara (MVA)” NCT00046397 ↗ |
| Known as | MVA85A/AERAS-485 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00953927 ↗ |
| Modality | Vaccine | “experimental vaccine called Modified Vaccinia Virus Ankara (MVA)” NCT00046397 ↗ |
| Route | Intramuscular | “administered by intramuscular (IM) injection” NCT00046397 ↗ |